Viatris!辉瑞和迈蓝合并公司名称来啦

导读:刚刚,全球仿制药第一巨头,辉瑞和Mylan命名为Viatris!

据药智网获悉,刚刚,全球仿制药第一巨头,辉瑞普强(Upjohn)和迈蓝(Mylan)宣布合并的公司名为Viatris(发音为‘viǝ-trīs)。预计在2020年中完成交易,届时仿制药巨头将以Viatris名字出现。


今年7月29日,辉瑞与迈蓝共同宣布,将迈蓝与辉瑞旗下专利到期品牌和仿制药业务部门—普强合并,以创建一家新的全球制药公司。辉瑞股东将拥有合并后新公司57%的股份,而迈蓝股东将拥有43%的股份。据报道称,辉瑞普强集团全球总裁高天磊(Michael Goettler)将成为合并后公司的首席执行官,迈蓝董事会主席RobertCoury将成为董事会执行主席。以及据知情人士透露,迈蓝现任首席执行官海瑟·布莱什(Heather Bresch)将离职,合并后的新公司设在美国。现合并新公司名称确认来袭,不久又一制药巨头将悄然升起。


附辉瑞与迈蓝交易原文:


HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs).


Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.


“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J. Coury, who will serve as Executive Chairman of the new company, as previously announced. “We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”


“The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced. “We have an opportunity to deliver better health, better care and better value for patients and partners around the world.”


Formed through a combination of two highly complementary businesses, Viatris will unite Upjohn’s strong leadership position in China and emerging markets with Mylan’s significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for Viatris’ broad product portfolio and future pipeline.


It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.


Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close.


Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.


“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J. Coury, who will serve as Executive Chairman of the new company, as previously announced. “We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”


“The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced. “We have an opportunity to deliver better health, better care and better value for patients and partners around the world.”


Formed through a combination of two highly complementary businesses, Viatris will unite Upjohn’s strong leadership position in China and emerging markets with Mylan’s significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for Viatris’ broad product portfolio and future pipeline.


It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.


Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close.


消息来源:药智网、辉瑞、药通社等网络公开信息。


QQ图片20191031092423.png

责任编辑:三七

声明:本文系整合内容,观点仅代表作者本人,不代表药智网立场,欢迎在留言区交流补充;如需转载,请务必注明文章作者和来源。

热门评论
请先 登录 再做评论~
发布

Copyright © 2009-2024 药智网YAOZH.COM All Rights Reserved.   工信部备案号:渝ICP备10200070号-3

渝公网安备 50010802001068号

投诉热线: (023) 6262 8397

邮箱: tousu@yaozh.com

QQ: 236960938